sinopharm featured image
News Pharmaceutical & Biotech Stories

Indonesia Approves Sinopharm COVID-19 Vaccine for EUA

Indonesia’s drug regulator approved the COVID-19 vaccine of China’s Sinopharm, which it will use in a private immunization scheme where companies buy government-procured vaccines to inoculate their staff.

After Sinovac Biotech and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia, which is seeking to inoculate 181.5 million people by January 2022.

It has suffered one of the worst COVID-19 outbreaks in Asia, with 1.66 million infections and more than 45,000 deaths reported.

According to Chief of Indonesia’s FDA, Penny K. Lukito, Sinopharm vaccine recipients had reported higher antibody rates and rare side effects, such as swelling or diarrhea.

“Based on the evaluation and the benefits or risks consideration … BPOM has issued an emergency use authorization (for Sinopharm),” she told a news conference.

Verdi Budidarmo, CEO of Pharmaceutical company Kimia Farma which distributes the vaccine, said the private vaccination program, which starts next month, could “back up the government to reach herd immunity”.

Over 482,000 ready-to-use doses of the Sinopharm vaccine arrived on Friday, May 7.

ASEAN HR TECH VENTURE SUMMIT 2018
REGISTER NOW 33% DISCOUNT
SUMMIT PASS